• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25 filed by Safeguard Scientifics Inc.

    2/2/24 6:01:59 AM ET
    $SFE
    Finance/Investors Services
    Finance
    Get the next $SFE alert in real time by email
    25 1 tm244919d1_25.htm 25

     

     

     

    UNITED STATES

    OMB APPROVAL

      SECURITIES AND EXCHANGE COMMISSION

    OMB Number:

    3235-0080

      Washington, D. C. 20549

    Expires:

    May 31, 2024
       
    FORM 25
    Estimated average burden hours per response 1.00

     

    NOTIFICATION OF REMOVAL FROM LISTING AND/OR

    REGISTRATION UNDER SECTION 12(b) OF THE

    SECURITIES EXCHANGE ACT OF 1934.

     

    Commission File Number

    001-05620

     

     

     Safeguard Scientifics, Inc.

     

    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

      

     

    150 N. Radnor Chester Rd., STE F-200, Radnor, PA 19087, 610-293-0600 

     

    (Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)

     

     

    Common Stock ($.10 par value)

     

    (Description of class of securities)

     

     

    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

     

    ¨17 CFR 240.12d2-2(a)(1)

     

    ¨17 CFR 240.12d2-2(a)(2)

     

    ¨17 CFR 240.12d2-2(a)(3)

     

    ¨17 CFR 240.12d2-2(a)(4)

     

    ¨    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.1

     

    x    Pursuant to 17 CFR 240.12d2-2(c),

     

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, Safeguard Scientifics, Inc (Name of Issuer or Exchange) certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

     

    February 2, 2024 By /s/ G. Matthew Barnard

    Special Counsel

          Title

     

     

     

    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

     

     

    SEC 1654 (03-06) Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.  

     

     

     

     

    GENERAL INSTRUCTIONS

     

    1.  This form is required by Rule 12d2-2 (17 CFR 240.12d2-2) of the General Rules and Regulations under the Securities Exchange Act of 1934 (“Exchange Act”).

     

    2.  Exchanges: Attach the delisting determination to this Form 25 to serve as the required Notice pursuant to Exchange Act Rul1e9d-1 (17 CFR 240.19d-1). Form 25 and the attached Notice will be considered compliance with the provisions of Rule 19d-1 as applicable

     

    3. The Form 25 and any attachments must be filed electronically on the EDGAR database.

     

    4.  The removal of the class of securities from listing on the exchange shall be effective 10 days after filing the Form 25. With respect to the filing of any amendment to Form 25, the removal of the class of securities from listing on the exchange shall be effective 10 days after filing the amended Form 25.

     

    5.  The withdrawal of registration of a class of securities registered under Section 12(b) of the Exchange Act shall take effect in 90 days, or such shorter period as the Commission may determine, after the exchange or issuer files a Form 25 with the Commission. With respect to the filing of any amendment to Form 25, the withdrawal of registration of a class of securities registered under Section 12(b) shall take effect in 90 days, or such shorter period as the Commission may determine, after the exchange or issuer files the amended Form 25.

     

    6.  For purposes of Section 12 of the Exchange Act, a class of securities shall no longer be considered listed on a national securities exchange upon the effective date of delisting even though the withdrawal of registration is effective at a later time.

     

    7.  The issuer’s duty to file any reports under Section 13(a) of the Exchange Act and the rules and regulations thereunder as a result of the security’s registration under Section 12(b) of the Exchange Act shall be suspended upon the effective date of the delisting. If, following the effective date of delisting, the withdrawal of registration under Section 12(b) is delayed by the Commission, an exchange, or an issuer, the issuer shall, within 60 days of such delay, file any reports that would have been required under Section 13(a) and the rules and regulations thereunder, had the Form 25 not been filed. The issuer will also file any subsequent reports required under Section 13(a) for the duration of the delay.

     

    8.  An issuer whose reporting responsibilities under Section 13(a) of the Exchange Act are suspended for a class of securities under Rule 12d2-2(d)(5) is, nevertheless, required to file any reports that an issuer with such a class of securities registered under Section 12 of the Exchange Act would be required to file under Section 13(a) if such class of securities:

     

    (a) is registered under Section 12(g) of the Exchange Act; or

     

    (b)  would be registered, or would be required to be registered, under Section 12(g) of the Exchange Act but for the exemption from registration under Section 12(g) provided by Section 12(g)(2)(A) of the Exchange Act.

     

    9.  An issuer whose reporting responsibilities under Section 13(a) of the Exchange Act are suspended under Rule 12d2-2(d)(5) is, nevertheless, required to file any reports that would be required under Section 15(d) of the Exchange Act but for the fact that the reporting obligations are: (a) suspended for a class of securities under Rule 12d2-2(d)(5); and (b) suspended, terminated, or otherwise absent under Section 12(g) of the Exchange Act. The reporting responsibilities of an issuer under Section 15(d) of the Exchange Act shall continue until the issuer is required to file reports under Section 13(a) of the Exchange Act or the issuer’s reporting responsibilities under Section 15(d) are otherwise suspended.

     

    10.  Issuers should determine if they have additional registration and reporting requirements under Section 12(g) of the Exchange Act and reporting obligations pursuant to Section 15(d) of the Exchange Act upon the filing of Form 25.

     

    11.  In any case where the Commission has commenced a proceeding under Section 12 of the Exchange Act prior to the withdrawal of the registration of a class of securities becoming effective, such security will remain registered under Section 12(b) of the Exchange Act until the final decision of such proceeding, or until the Commission otherwise determines to suspend the effective date of, or revoke, the registration of a class of securities.

     

    12.  In the event removal is being effected under Rule 12d2-2(a)(3) and the national securities exchange has admitted or intends to admit a successor security to trading under the temporary exemption provided for by Exchange Act Rule 12a-5 (17 CFR 240.12a-5) the Form 25 shall be filed with the Commission in a manner that ensures that the delisting does not become effective until the successor security is removed from its exempt status.

     

     

     

    Get the next $SFE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SFE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SFE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Safeguard Scientifics Filed Form 25 to Voluntarily Delist its Common Stock from The Nasdaq Stock Market LLC

    RADNOR, Pa., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Safeguard Scientifics, Inc. (NASDAQ:SFE) ("Safeguard" or the "Company") has announced today that it filed Form 25 with the Securities and Exchange Commission (the "SEC") to voluntarily delist its shares of common stock from trading on The Nasdaq Stock Market LLC ("Nasdaq") in connection with its previously announced plan to deregister its common stock under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and to delist the Company's common stock from trading on Nasdaq (referred to as the "Transaction"). The Company expects that the delisting will occur ten days after the filing of Form 25 so that trading will be suspended

    2/2/24 8:30:00 AM ET
    $SFE
    Finance/Investors Services
    Finance

    Safeguard Scientifics Intends to File Form 25 to Voluntarily Delist its Common Stock from The Nasdaq Stock Market LLC

    Radnor, Pa, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Safeguard Scientifics, Inc. (NASDAQ:SFE) ("Safeguard" or the "Company") has announced today that it notified The Nasdaq Stock Market LLC ("Nasdaq") that it intends to file Form 25 with the Securities and Exchange Commission (the "SEC") on February 2, 2024 to voluntarily delist its shares of common stock from trading on Nasdaq in connection with its previously announced plan to deregister its common stock under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Company expects that the delisting will occur ten days after the filing of Form 25, at which point, the Company intends to file a Form 15 with the SEC certifying

    1/22/24 4:30:00 PM ET
    $SFE
    Finance/Investors Services
    Finance

    Safeguard Scientifics Announces Effective Date of Stock Splits to Effectuate the Going Dark Transaction and New Chief Executive Officer and Chief Financial Officer

    RADNOR, Pa., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Safeguard Scientifics, Inc. (NASDAQ:SFE) ("Safeguard" or the "Company") today announced that, as authorized by its Board of Directors (the "Board"), the Company will file amendments to its articles of incorporation with the Pennsylvania Department of State to effectuate a reverse stock split at a ratio of 1-for-100, to be followed immediately by a forward stock split at a ratio of 100-for-1 (collectively referred to as "stock splits"), which are expected to become effective on or about January 12, 2024, and the Company's common stock is expected to begin trading on The Nasdaq Stock Market LLC ("Nasdaq") on a post-forward stock split basis upon

    1/5/24 4:30:00 PM ET
    $SFE
    Finance/Investors Services
    Finance

    $SFE
    SEC Filings

    View All

    SEC Form 15-12G filed by Safeguard Scientifics Inc.

    15-12G - SAFEGUARD SCIENTIFICS INC (0000086115) (Filer)

    2/20/24 3:02:10 PM ET
    $SFE
    Finance/Investors Services
    Finance

    SEC Form SC 13E3/A filed by Safeguard Scientifics Inc. (Amendment)

    SC 13E3/A - SAFEGUARD SCIENTIFICS INC (0000086115) (Subject)

    2/20/24 3:01:28 PM ET
    $SFE
    Finance/Investors Services
    Finance

    SEC Form EFFECT filed by Safeguard Scientifics Inc.

    EFFECT - SAFEGUARD SCIENTIFICS INC (0000086115) (Filer)

    2/20/24 12:15:21 AM ET
    $SFE
    Finance/Investors Services
    Finance

    $SFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Manko Joseph M. Jr. was granted 38,087 shares, increasing direct ownership by 20% to 232,323 units (SEC Form 4)

    4 - SAFEGUARD SCIENTIFICS INC (0000086115) (Issuer)

    2/1/24 2:36:21 PM ET
    $SFE
    Finance/Investors Services
    Finance

    Demont Ross D was granted 20,775 shares, increasing direct ownership by 8% to 287,256 units (SEC Form 4)

    4 - SAFEGUARD SCIENTIFICS INC (0000086115) (Issuer)

    1/31/24 9:19:37 AM ET
    $SFE
    Finance/Investors Services
    Finance

    Michelson Beth was granted 22,506 shares, increasing direct ownership by 22% to 126,352 units (SEC Form 4)

    4 - SAFEGUARD SCIENTIFICS INC (0000086115) (Issuer)

    1/31/24 9:09:45 AM ET
    $SFE
    Finance/Investors Services
    Finance

    $SFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Safeguard Scientifics Inc. (Amendment)

    SC 13G/A - SAFEGUARD SCIENTIFICS INC (0000086115) (Subject)

    2/14/24 5:04:07 PM ET
    $SFE
    Finance/Investors Services
    Finance

    SEC Form SC 13G/A filed by Safeguard Scientifics Inc. (Amendment)

    SC 13G/A - SAFEGUARD SCIENTIFICS INC (0000086115) (Subject)

    2/14/24 4:05:40 PM ET
    $SFE
    Finance/Investors Services
    Finance

    SEC Form SC 13G/A filed by Safeguard Scientifics Inc. (Amendment)

    SC 13G/A - SAFEGUARD SCIENTIFICS INC (0000086115) (Subject)

    2/12/24 4:59:41 PM ET
    $SFE
    Finance/Investors Services
    Finance

    $SFE
    Leadership Updates

    Live Leadership Updates

    View All

    TheracosBio Announces the Appointments of Jim Greenwood to Board of Directors and Jeff McGroarty as Chief Financial Officer

    TheracosBio today announced the appointment of former US Congressman Jim Greenwood to the Board of Directors of its parent company and Jeff McGroarty, MBA, as its Chief Financial Officer. Congressman Greenwood is an established leader in life sciences across business and public policy, and Mr. McGroarty has served as a CFO of public and private life sciences and technology companies. Both newly appointed team members will help shape the commercial strategy for Brenzavvy™ (bexagliflozin), a recently FDA-approved treatment for type 2 diabetes. "Accomplished leaders, Jim and Jeff will be valuable members of our team at this critical time for TheracosBio," said Albert R. Collinson, Ph.D., Pres

    3/13/23 8:00:00 AM ET
    $ANVS
    $SFE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance/Investors Services
    Finance

    Safeguard Scientifics Announces Appointment Of Eric C. Salzman As CEO

    RADNOR, Pa., Dec. 21, 2020 /PRNewswire/ -- Safeguard Scientifics, Inc. (NYSE:SFE) announced today that Eric C. Salzman has been appointed Chief Executive Officer, effective December 21, 2020.  Since April 1, 2020, Mr. Salzman has served as the Company's Chief Restructuring Officer. As CEO, Mr. Salzman will continue to focus on the value maximization and monetization of Safeguard's interests in its portfolio companies as well as the management of Safeguard's operations. "Since joining Safeguard earlier this year, we have been impressed with Eric's progress towards executing on Safeguard's strategy to drive value creation from the portfolio and return capital to our shareholders," said Robe

    12/21/20 8:00:00 AM ET
    $SFE
    Finance/Investors Services
    Finance

    $SFE
    Financials

    Live finance-specific insights

    View All

    Safeguard Scientifics Announces Stock Split Ratios to Effectuate the Going Dark Transaction

    RADNOR, Pa., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Safeguard Scientifics, Inc. (NASDAQ:SFE) ("Safeguard" or the "Company") today announced that, after the Company's shareholders adopted amendments to the articles of incorporation at the Special Meeting of Shareholders held on December 15, 2023 (the "Special Meeting") to effect a reverse stock split, to be followed immediately by a forward stock split, at a ratio of (i) not less than 1-for-50 and not greater than 1-for-100, in the case of the reverse stock split, and (ii) not less than 50-for-1 and not greater than 100-for-1, in the case of the forward stock split (collectively referred to as "stock splits"), the Company's Board of Directors (t

    12/18/23 4:30:00 PM ET
    $SFE
    Finance/Investors Services
    Finance

    Safeguard Scientifics' Board of Directors Declares Contingent Cash Dividend of $0.35 Per Share

    RADNOR, Pa., Dec. 08, 2023 (GLOBE NEWSWIRE) -- Safeguard Scientifics, Inc. (NASDAQ:SFE) ("Safeguard" or the "Company") today announced that on December 7, 2023, its Board of Directors (the "Board") declared a special cash dividend of $0.35 per share, payable on December 28, 2023 to shareholders of record as of the close of business on December 19, 2023 (the "Record Date"). The dividend is contingent on the adoption of amendments to the Company's articles of incorporation effecting the reverse stock split and the forward stock split of the Company's common stock at the Special Meeting of Shareholders to be held on December 15, 2023, and the Board thereafter giving effect to the Company's

    12/8/23 4:30:00 PM ET
    $SFE
    Finance/Investors Services
    Finance

    Safeguard Scientifics Announces Third Quarter 2023 Financial Results

    RADNOR, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Safeguard Scientifics, Inc. (NASDAQ:SFE) ("Safeguard" or the "Company") today announced financial results for the three and nine months ended September 30, 2023. THIRD QUARTER 2023 HIGHLIGHTS Financial Results Cash, cash equivalents and restricted cash totaled $15.7 million at September 30, 2023.The carrying value of the Company's ownership interests totaled $14.8 million at September 30, 2023. The total cost of the Company's ownership interests was $122.8 million.Net income for the three months ended September 30, 2023 was $0.9 million, or $0.06 per basic and fully diluted share, as compared with a net loss of $3.2 million, or $0.19 per bas

    11/2/23 4:30:03 PM ET
    $SFE
    Finance/Investors Services
    Finance